Index

absorption 42, 45, 46–7
academic context 63–71
academic detailing 67
academic medical centers 68–9, 70–1
case example 70–1
collaborative research 69
drug approval process 64
economic assessments 68
funding 411–12
future developments 69, 407, 408–13
interventional pharmacoepidemiology 67–8
logistical advances 411
methodological advances 408–9
new content areas of interest 409–11
patients’ use of drugs 65–6, 67
personnel 412–13
policy analysis 67
postmarketing surveillance studies 63–4
prescribing practices 64–5, 67–8, 348
quality and outcomes of medication use 66–7
risk-benefit assessment 63
scientific developments 408–11
accessibility of data 141, 149–52, 159–60
accuracy of data 139, 158–9, 206, 210, 212–18, 353
adherence 314–23
academic context 65–6, 67
challenges in adherence measurement 315–16
clinical trials 315, 320
data analysis 316, 320–1
drug concentration assays 319
electronic drug monitors 318–20, 321–2
future developments 321–2, 410
medication diaries 318, 319
medication errors 382
metrics 321
non-pill formulations 319–20, 322
pill counts 318
refill data 317–18, 321
self-reported data 316–17, 319, 321
time-vary nature and duration of adherence intervals 320–1
administrative databases 119–21, 122, 124–5, 360, 368
adverse drug events (ADEs) 378–80, 384
adverse drug reactions (ADRs)
causation 229
drug utilization studies 341
early legislation 5–6
intellectual development of pharmacoepidemiology 9–11
legal and regulatory context 3
meta-analysis 300–1, 308–10
molecular pharmacoepidemiology 242
pharmacovigilance 4–5
regulatory actions resulting from drug crises 6–8
spontaneous reporting 102–16
Type A and Type B reactions 3–4
Adverse Event Reporting System (AERS) 9, 104, 105, 108, 386, 391
adverse events (AEs)
academic context 64
causation 228–38
industry context 73–4
legal context 88
meta-analysis 308–10
pharmacoeconomics 285
pharmacovigilance 5
spontaneous reporting 102–16
adverse events following immunizations (AEFIs) 350–5
Agency for Healthcare Research and Quality (AHRQ) 10–11
academic context 69, 412–14
automated databases 129, 131
comparative effectiveness research 393, 399–400
future developments 412–14
implantable medical devices 360
analyses of secular trends 21, 22, 23–4, 27
Anatomical Therapeutic Chemical (ATC) codes 158, 167, 187, 344
approved patient labeling 71, 374–5
association
causal association 17, 20–21
causation 229
criteria for the causal nature of an association 20–1

© 2013 John Wiley & Sons, Ltd. Published 2013 by John Wiley & Sons, Ltd.
association (Continued)
epidemiologic study designs 24–8
error types 18–20
measurement error 208–12
molecular pharmacoepidemiology 241–4, 246–54
scientific method 17, 18
strength, consistency and specificity 20–1
validity of data 208–12
automated databases 118–22, 123–77
bioethics 262
Canadian provincial databases 144–52
claims and other administrative databases 119–21, 122,
124–5, 133–44
comparative effectiveness research 396–7
confounding variables 324–5, 332–3
data resources comparison 191–5
drug utilization studies 342–4, 346
future developments 122, 411
health maintenance organizations/health plans 123–33
implantable medical devices 360
medical record databases 120–1, 122, 152–63
medication errors 383–4
particular applications 121–2, 126–31, 142–3, 150–1,
161, 170–2
pharmacy-based medical record linkage
systems 163–73
research questions comparison 195–201
Sentinel Initiative 385, 388, 391–2
standard data layouts 129
strengths and weaknesses 120–1, 125–6, 139–42, 150,
159–61, 169–70
teratogenicity 368
vaccine safety 354–5
validity of data 221–4
Bayesian analysis 109, 114, 234–5, 306
biases 19–20
adherence 317
bioethics 267–8
comparative effectiveness research 398–9
field studies 179–80
medication errors 382–3
meta-analysis 300–2, 303–4, 306–7
randomized controlled trials 271–2, 276
teratogenicity 366
vaccine safety 353
validity of data 206–7, 211–12
see also confounding variables
bioavailability 43
bioethics 256–68
automated databases 262
case example 267
comparative effectiveness research 399
confidentiality 149
ethics review boards 261, 262–8
human subjects research 256–7, 258, 266–7
informed consent 67, 150, 259–60, 262, 267, 287
minimal risk 260–1
pharmacoepidemiologic research 257–8
potential contributions of pharmacoepidemiology 15
prescribing practices 347
privacy and confidentiality 258–9, 263–4, 266–7
biologic plausibility 20, 367
biological samples 186
birth defects see teratogenicity
birth registers 166, 168–9, 172
black triangle program 106–7
blinding 272
body composition 45–6, 47
Bradford Hill criteria 89
British National Formulary 106–7
broad drug safety initiatives 77
calendar time cohorts 326
Canadian provincial databases 144–52
case example 152–3
data resources comparison 191–5
health services program 144–5, 152–3
hospitalization databases 148–9
medical services databases 147–8
particular applications 150–1
prescription drug databases 145–7, 151–3
research questions comparison 195–201
strengths and weaknesses 150
cancer registries 166, 168, 171
candidate gene approach 246–7, 250
capacity building 79, 84–5
case–cohort studies 327–8
case-control studies
bioethics 262
data resources comparison 191–2, 192–5
field studies 182–3, 185
molecular pharmacoepidemiology 247–51
research questions comparison 195–6, 199
sample size 31, 33–9
study designs 22, 23–7
teratogenicity 369
validity of data 206–7, 209–11
case–crossover studies 325, 328–30
case-only studies 250–1
case report forms (CRFs) 181
case reports 22–3, 27, 105–6, 109–12, 181–2, 228–38
case series 22, 23, 27, 36–7, 110, 114
case–time–control studies 329–30
causal association 17, 20–21
causation
algorithm/criterial method with verbal judgments 233
algorithms requiring scoring of individual
judgments 233–4
case example 230–1
case reports 228–38
current tools and methods 233–5
future developments 236
historical perspectives 229–31
industry context 231–2
legal context 88–9
molecular pharmacoepidemiology 243–4
probabilistic methods 234–5
randomized controlled trials 270
regulatory context 232
reports to medical journals 232
spontaneous reporting 102–3, 107–11
study designs 17, 18
unstructured clinical judgment/global introspection 233
uses of causality assessment 231–2
vaccine safety 351–3
Centers for Disease Control and Prevention (CDC) 129, 354–5, 369, 414
Centers for Education and Research on Therapeutics (CERTs) 10, 85, 399, 412
Centers for Medicare and Medicaid Services (CMS) 133–8, 185, 394
chart review 383
claims databases 119–21, 123–6 133–44
case example 143–4
data resources comparison 191–5
data sources and structure 134, 137–9
demographic data 134–8
implantable medical devices 360
Medicaid/Medicare programs 133–7, 139–44
medication errors 383
particular applications 142–3
research questions comparison 195–201
strengths and weaknesses 139–42
Veterans Affairs health care 135–6, 138–44, 223–4, 344
clearance 44, 46, 49
clinical context 55, 57–8, 62
clinical decision support systems (CDSS) 378–9, 382
clinical feedback 348
clinical laboratory data 168, 170–1
clinical pharmacology
absorption 42, 45, 46–7
basic principles 40–53
drug interactions 48–9
elderly patients 45–6
elimination 44, 46, 49
metabolism 43–4, 48
organ impairment 48
pediatric patients 46–7
pharmacodynamics 4, 40, 49–50
pharmacoepidemiology versus 3–5, 40–1
pharmacogenomics 50–1
pharmacokinetics 4, 40, 41–9
pharmacovigilance 4–5
pregnancy 47–8
special populations 44–9
study designs 17
Type A and Type B reactions 3–4
volume of distribution 42–3, 45–6, 48
clinical trials
adherence 315, 320
comparative effectiveness research 396–9
health-related quality-of-life 294–5
meta-analysis 308–9
pharmacoeconomics 285–6, 287–8
pharmacoepidemiology versus epidemiology 5
regulatory context 81
United States context 12
see also randomized clinical trials
Cochrane Collaboration 303, 399
Code of Federal Regulations (CFR) 258–61, 265
cohere with existing information 20
cohort studies
case–cohort studies 327–8
confounding variables 325–8, 334
data resources comparison 191–2, 193
nested case-control studies 327
research questions comparison 195–6, 198, 199
sample size 30–3, 37–9
structures of cohorts 326–7
study designs 21, 22, 24–8
teratogenicity 367
collaborative research
academic context 69
automated databases 125, 126, 129, 130
implantable medical devices 363
industry context 76–7, 78
regulatory context 79, 84–5
see also Sentinel Initiative
Committee for Medicinal Products for Human Use (CHMP) 13, 72
comparability of study groups 331–2, 358
comparative effectiveness research (CER) 11, 126, 129, 393–401
automated databases 151
cost containment 401
current applications 400
definition of effectiveness 394
definitions of comparative effectiveness research 395
dissemination of evidence 399, 401
experimental studies 398–9
funding 400
future developments 400–401, 408, 410
generation of evidence 397–9, 401
historical developments 393–4
human capital development 400
implantable medical devices 356
nonexperimental studies 397–8
organizational approaches 399–400
reasonable expectations for 401
synthesis of evidence 396, 401
completeness of data 158–9, 160–2, 169–70, 206–7, 210–12, 222–4
computerized order-entry systems 68
computerized physician order entry (CPOE) 378–9, 382
concentration-effect relationships 49–50
confidence intervals 26, 30, 37, 289
confidentiality 91–2, 149, 258–9, 263–4, 266–7
confounding variables 19–20, 324–36
analysis of comparable patients 331–2
analytic approaches for improved confounding control 330–4
automated databases 121, 141
balancing patient characteristics 330
case–cohort studies 327–8
case–crossover studies 325, 328–30
case examples 335–6
case–time–control studies 329–30
cohort studies 325–8, 334
comparative effectiveness research 397
data resources comparison 191–2, 194
exposure variation 325
field studies 181
future developments 409
industry context 74–5
instrumental variable analysis 333
molecular pharmacoepidemiology 249–50, 252
nested case–control studies 327–8
new user design principle 325
propensity score analysis 330–1, 332, 335–6
proxy adjustment 332–3, 334
random aspects in treatment choice 333
randomized controlled trials 270–1, 274–5
research questions comparison 195–6, 198–9
sensitivity analysis 333–4
study designs 325–30
teratogenicity 367
unobserved patient characteristics and residual confounding 332
vaccine safety 353
validity of data 205–6
within-subject designs 325, 328–30
Congressional Budget Office 395
consistency of data 308
constructive knowledge 87–8
continuity corrections 305–6
continuous outcome variables 38
contract law 90–2, 93
control groups 32–6, 38–9
cooperativity of study population 275–6
copy number variants (CNV) 240
correlation coefficients 208
cost-effectiveness analysis 283–4, 285, 289
costs
comparative effectiveness research 401
drug utilization studies 341–2
field studies 179
patients’ use of drugs 66
pharmacoeconomics 281, 284, 288–9
risk-benefit assessment 54, 62
criterial method with verbal judgments 233
critical score algorithm 231, 234
cross-sectional construct validity 293
cross-sectional studies 27
cross-sector partnerships 77
cumulative meta-analysis 309–10
cytocrome P450 (CYP) enzymes 43–4, 46, 48, 242, 245
data analysis
adherence 316, 320–1
field studies 187–8
meta-analysis 304–6
pharmacoeconomics 287–9
randomized controlled trials 272, 277
data collection
field studies 181–3, 185–6
medical record databases 155–8
meta-analysis 303–4
pharmacoeconomics 287
randomized controlled trials 272, 273–4
study designs 190
Data Extraction and Longitudinal Time Analysis (DEcIDE) 359
data limitations 141
data management 186–7
data mining 109, 114–15, 117, 408
data monitoring 277
data security 386, 391
data structure 134–5, 137–9, 155–8, 390
Daubert v. Merrell Dow 89–90
Dear Healthcare Professional Letters 71, 104, 115, 374
death registers 157, 166, 168–9
Declaration of Helsinki 261
defined daily dose (DDD) 342–4
demographic data
automated databases 124, 128, 134–7, 140, 146–8, 156
validity of data 215, 218
Developing Evidence to Inform Decisions about Effectiveness (DEcIDE) 69, 130–1, 399
device variation 361
diagnosis data 124, 216–18, 222–3
differential misclassification 209–12
direct-to-customer advertising (DTCA) 88
disease area-specific collaborations 77
disproportionality 109, 114
dose–response relationships 21, 40, 103
drug approval process 11–13, 64
drug concentration assays 319
drug development process 281
drug–event pairs 109, 114–15, 117
drug-induced birth defects 367
drug interactions 48–9, 103, 241–4, 247–8, 250–1, 275, 381–2
drug safety initiatives 76–7
Kefauver-Harris Amendments 9
knowledge liability 87–8
large simple trials (LSTs) 74–5, 79, 273–8
learned intermediary rule 88, 93
legal context 86–94
    adverse drug reactions 3
    contract law and pharmacoepidemiology 90–2, 93
    early legislation 5–6
    failure-to-warn liability 87–9, 93
    future developments 414
    intellectual property law and
    pharmacoepidemiology 92, 93–4
    legislative actions resulting from drug crises 8–9
    pharmacoepidemiologic expertise and
    Daubert 89–90
    potential contributions of pharmacoepidemiology 15
    prescribing practices 347
    risk-benefit assessment 55, 57, 62
    risk management 370–1
    tort law and product liability 86–90, 93
life-cycle approach 386, 388
linkage capacity 140, 149–50
linkage disequilibrium (LD) 242, 250
literature reviews 300, 302–3
    see also meta-analysis
long-term safety 356–7
longitudinal construct validity 293
mandated postmarketing studies 359–60
Mantel–Haenszel procedure 304, 305–6, 329
Manufacturer and User Facility Device Experience
    (MAUDE) database 358, 391
marketing context 55, 56–7, 62
Markov chain Monte Carlo techniques 306
maternal linkage 168–9
measurement error 206–12, 220
    adherence 318
    association 211–12
    indices of 206–8
    misclassification of variables 209–12, 226, 318
    pharmacoepidemiologic research 208–12
    quantitative measurement of reliability 206, 208
    quantitative measurement of validity 206–8
Medicaid program 133–7, 139–44, 222
medical journals 232, 407
medical record databases 120–1, 122, 152–63
    bioethics 262
    case example 162–3
    data collection and structure 155–8
    data resources comparison 191–5
    description 155–9
    particular applications 161
    research questions comparison 195–201
    strengths and weaknesses 159–61
    medical services databases 147–8
medication adherence see adherence
drug utilization studies 341
future developments 384, 410
generalizability 383
information bias 382–3
patient safety concepts 379–80
safety theory 378–9
sample size 383
spontaneous reporting 105
Medication Guides 374–5
MedWatch program 8, 9, 103–4
membership status data 124
meta-analysis 300–13
    analysis of rare events 305–6
    bias in the abstraction of data 302
    choice of statistical method 304–5
    comparative effectiveness research 396–7
    compatibility of studies 301
    conclusions and recommendations 306
    confounding variables 335–6
    cumulative meta-analysis 309–10
    data analysis 304–6
    data collection 303–4
    defining the purpose 302
    differential effects among patient subgroups 308–9
    effect measurement 304
    future developments 311–12
    implantable medical devices 358
    inclusion/exclusion criteria 303
    indirect and simultaneous comparison of
    treatments 307–8, 311–12
    literature reviews 300, 302–3
    procedural steps 302–7
    publication bias 301–2, 306–7
    regulatory context 311
    signal detection 309–10
    susceptibility of original studies to bias 301
    variability and heterogeneity 304–5
metabolism 43–4, 48
meta-regression 305
Michaelis Menten kinetics 43
Mini-Sentinel 131, 385, 387, 392–3
minimal important difference (MID) 294–5
minimum effect size 31–3
misclassification of variables 209–12, 226, 318
missing heritability 246–7
molecular pharmacoepidemiology 239–55
    case examples 243, 245, 251
    confounding by population admixture 249–50
definitions and concepts 239–40
future developments 252–3
genetic variability 239–40, 247
molecular pharmacoepidemiology (Continued)
gene–drug interactions and causation 243–4, 250–1
gene–drug interactions and effect modification 247–8
genome-wide versus candidate gene approaches 246–7, 250
interplay of various mechanisms 244
pharmacodynamic gene–drug interactions 242–3
pharmacogenetics and pharmacogenomics 240–1, 244–7, 253
pharmacokinetic gene–drug interactions 241–2
replication 252
research progression and application 244–5
type I/II errors 248–9, 252
multicenter evaluations 287
multi-HMO collaborations 125, 126–7, 129
Multi-item Gamma Poisson Shrinker 109
multinational economic evaluation 283

Naranjo scored algorithm 231, 234
National Drug Code (NDC) 124, 344, 357
National Institute for Health and Clinical Excellence (NICE) 11, 394
National Institutes of Health (NIH) 129, 399, 411–14
national pharmacovigilance systems 106–7
national postmarketing safety databases 108–9
negative predictive value 207, 223–4
negligence 87
nested case-control studies 327–8
New Drug Applications (NDAs) 72
new user design principle 325
nondifferential misclassification 209–12
nonrepresentativeness 140
nonresponse bias 267
number needed to treat (NNT) 296, 298
number of prescriptions 342

odds ratios 25–6, 33, 36, 39, 247–9, 304–5
once-daily therapies 321–2
one-step model 306
orphan drug applications 71
out of plan care 142
over-the-counter (OTC) medications 74, 118, 366, 369–70

patents 92, 93–4
pathology data 166, 168, 171
Patient Package Inserts 71, 374–5
patient router files 166–7
patient variation 361
pediatric investigation plans (PIP) 71, 74
pediatric patients 46–7, 383
Peto method 306
pharmacodynamics 4, 40, 49–50, 242–3, 316, 318
pharmacoeconomics 280–90
academic context 68

analysis of economic and costs data 287–9
case examples 282–3
clinical trials versus common practice 285–6
cost-effectiveness analysis 283–4, 285, 289
data collection 287
drug development process 281
future developments 289–90, 409
measurement and modeling in clinical trials 287–8
multicenter evaluations 287
participation of patients 287
perspective of analysis 284
prospective studies 286–9
research trends 280–1
sample size 286–7
sensitivity analysis 284
study designs 286–9
types of costs 281, 284
uncertainty in economic assessment 289
pharmacoepidemiology, definition 3
pharmacogenetics 240–1, 244–7, 253, 408–9
pharmacogenomics 50–1, 240–1
pharmacokinetics 41–9, 241–2, 316, 318
pharmacovigilance 4–5
adverse events and adverse drug reactions 102–16
case example 116
causation 102–3, 107–11
concept of spontaneous AE/ADR reporting 103–4
future developments 115
national and international postmarketing safety databases 108–9
national pharmacovigilance systems 106–7
non-uniform temporal reporting trends 113–14
opportunity for public reporting 112
overview of pharmacovigilance reporting systems 102–3
particular applications of spontaneous reporting 114–15
report characteristics 105–6
report quality 113
reporting ratios 111–12, 114, 117
scope of postmarketing safety reporting systems 112–13
signal detection 108–9, 112, 114–15, 117
signals from developing countries 115
spontaneous reporting 8, 101–17
strengths and limitations 112–14
underreporting 113
pharmacy-based medical record linkage (PbMRLs) systems 163–73
births, deaths and maternal linkage 166, 168–9, 172
cancer registries 166, 168, 171
case example 172–3
clinical laboratory data 168, 170–1
data resources comparison 191–5
description 164–9
exposure databases 167, 170
hospitalization data 166, 167, 171–2
particular applications 170–2
pathology data 166, 168, 171
patient router files 166–7
record linkage 164–6
research questions comparison 195–201
strengths and weaknesses 169–70
pharmacy claims records 139
PHARMO record linkage system 164–73
pill counts 318
pilot studies 183–4
placebo-controlled trials 301, 307–8, 398
population-based data 159, 161, 191, 193
population size 139
population stratification 249–50, 252
positive predictive value 207, 223–4
Post-Approval Studies (PAS) Program 359
Post-authorization Safety Studies (PASS) 72
postmarketing requirements (PMR) 72
postmarketing surveillance studies
academic context 63–4, 69
adherence 315
drug approval process 12–13
implantable medical devices 359–60
pharmacoepidemiology versus epidemiology 5
potential contributions of
pharmacoepidemiology 14–15
risk-benefit assessment 55–8
sample size 37
Sentinel Initiative 384–5, 391
spontaneous reporting 8, 101–17
study designs 23, 27
pragmatic clinical trials 398–8
PRECEDE framework 347–8
predictive value 207, 223–4
pregnancy 47–8, 157, 382–3
see also teratogenicity
prescribed daily dose (PDD) 344
prescribing practices
academic context 64–5, 67–8
adherence 317–18, 321
automated databases 139, 141, 144–7, 150–3, 165, 169
case example 349
conceptual framework 347–8
detecting effects on patient outcomes 347
drug utilization studies 342, 344
empirical evidence on effectiveness of interventions 348
ethical and medico-legal problems with RCTs 347
evaluating and improving 346–50
future developments 348–50
internal validity 346–7
number of prescriptions 342
patient as unit of analysis 347
refill data 317–18, 321
regression toward the mean 347
teratogenicity 366, 369–70
prescription drug databases 145–7, 151–3
Prescription Drug User Fee Act (PDUFA) 8–10, 71, 75
Prescription Event Monitoring (PEM) 9, 191–201
prevalence rates 33, 36, 161, 195, 198, 345
primary outcomes 277
prior written consent 91
privacy 258–9, 263–4, 266–7, 386, 391
probabilistic methods 234–5
procedures data 125
product liability 86–90, 93
propensity score (PS) analysis 330–1, 332, 335–6, 408, 409
prospective studies 27–8, 286–9
protected health information (PHI) 391
protocol development 181
protocol-induced testing 285
provider variation 361
proxy adjustment 332–3, 334
publication bias 301–2, 306–7
quality control (QC) 186–7
Quality and Outcomes Framework (QOF) 158
quality scoring systems 303
quality-adjusted life-years (QALYs) 297
quality-of-life measurements see health-related quality-of-life
quantitative strength 21
questionnaire design 214–15, 218–20
random-effects models 304–5
randomized clinical trials (RCTs)
comparative effectiveness research 397–8
ethical and medico-legal problems 347
health-related quality-of-life 295–6
implantable medical devices 356, 357–8
industry context 73, 74
study designs 21, 22, 26–8
randomized controlled trials (RCTs) 269–79
adherence 315
appropriateness of large simple trials 274–5
blinding 272
case examples 270
choice of control treatment 272
data collection and analysis 272, 273–4, 277
feasibility of large simple trials 275–6
future developments 277–8
large simple trials 273–8
limitations 272–3
logistics of large simple trials 276–7
meta-analysis 309–10
overview of classic RCTs 271–2
research questions 274
sample size 271–2, 273
Index

teratogenicity 364–5
vaccine safety 353
selection bias 179, 212
self-administered questionnaires 181–2
self-reported data 212–18, 221, 316–17, 319, 321
sensitivity analysis 211–12, 284, 333–4
see also completeness of data
Sentinel Initiative 384–93
academic context 69
automated databases 122, 131
case example 386
data infrastructure 390
data structure 390
database linkages 390–1
developing methods for signal generation 389–90
foundational aspects of 385–7
future developments 392, 411
governance 391, 393
industry context 77
operational challenges 391
privacy and data security 386, 391
regulatory context 85
standardized data elements 390
summary measures from multiple observational data sources 389
surveillance modes 385, 388, 390
validating a safety signal 388–9
signal detection
meta-analysis 309–10
pharmacovigilance 108–9, 112, 114–15, 117
vaccine safety 351, 353–4
signal evaluation 385, 388–9
signal generation 385, 389–90
signal refinement 385
signal-to-noise ratio (SNR) 293
similarity of data distribution 307–8
single nucleotide polymorphisms (SNPs) 51, 240–2, 250
small study effects 306
socioeconomic status 270–1
special populations 44–9
drug interactions 48–9
elderly patients 45–6
organ impairment 48
pediatric patients 46–7, 383
pregnancy 47–8, 157, 382–3
specificity of data 206–7, 211, 223–4
spontaneous reporting 8, 101–17
adverse events and adverse drug reactions 102–16
case example 116
case reports 105–6, 109–12
causation 102–3, 107–11
concept of spontaneous AE/ADR reporting 103–4
data resources comparison 191–5
future developments 115
medication errors 383
national pharmacovigilance systems 106–7
national/international postmarketing safety databases 108–9
non-uniform temporal reporting trends 113–14
opportunity for public reporting 112
overview of pharmacovigilance reporting systems 102–3
particular applications 114–15
report characteristics 105–6
report quality 113
reporting ratios 111–12, 114, 117
research questions comparison 195–201
scope of postmarketing safety reporting systems 112–13
signal detection 108–9, 112, 114–15, 117
signals from developing countries 115
strengths and limitations 112–14
underreporting 113
vaccine safety 352, 353–4
standard data layouts 129, 384, 390
standard error of measurement (SEM) 295
standardized incidence ratio (SIR) 327
standardized mortality ratio (SMR) 327
statistical inference 18
statistical power 31–3, 38, 273, 274–5, 369
stratified analysis 247–8, 305
study designs 17–29
advantages and disadvantages 21–2
analyses of secular trends 21, 22, 23–4, 27
automated databases 159
case-only studies 250–1
case series 22, 23, 27, 36–7, 110, 114
causal association 17, 19–21
clinical pharmacology 17
confounding variables 325–30
data resources comparison 190–5
error types 18–20
field studies 180–2
industry context 73–5, 78–9
integrating data from multiple sources 79, 83–4
large simplified trial 74–5, 78–9
pharmacoeconomics 286–9
regulatory context 79, 83–4
research questions comparison 190, 195–201
sample size 17, 30–9
scientific method 17–18
selection of study subjects 17–18
teratogenicity 367–9
see also individual study types
subgroup analyses 277, 308–9
subject enrollment 184–5
subpopulation-specific collaborations 77
Summary of Product Characteristics (SmPC) 374–5
supplementary information 13, 14
surrogate markers 410
surveillance modes 358–9, 385, 388, 390

455
Index

456

system-based interventions 382
systematic reviews 358, 396–7
Systemized Nomenclature of Medicine (SNOMED) 168
systems approach 386

teratogenicity 363–70
alleged/unknown teratogenic risk 364
automated databases 368
biologic plausibility 367
case example 365
class action teratogenesis 364
confounding variables 367
follow-up of selected exposures 368
future developments 369–70
integrated approaches 369–70
known teratogens 363–4
legal context 369
prescription and nonprescription drugs 366, 369–70
recall bias 366
regulatory actions resulting from drug crises 6–7
regulatory context 369
sample size 364–5
study designs 367–9
termination of pregnancy 367
therapeutic window 52
time sequence of events 20–1
time-to-refill approach 317–18
tort law 86–90, 93
toxicity 49, 315
transparency 109, 386
two-tailed tests 31, 32–5
Type A/B reactions 3–4
type I/II errors 30–1, 32–6, 38–9, 54, 248–9, 252

unavailable information 141
uncertainty 274, 289
unexpected effects 197–8
unique device identifiers (UDIs) 357, 361
universal consent 262
unstructured clinical judgment 233
use patterns of a medicine 65–6, 67, 83, 86, 150
see also adherence
utility measurement 297

Vaccine Adverse Event Reporting System (VAERS) 108, 352, 353–4, 391
vaccine safety 350–5
case example 352
causation 351–3
confounding and bias 353
confounding variables 335

epidemiologic studies 354
future developments 354, 410–11
measurement accuracy 353
sample size 353
Sentinel Initiative 391
signal detection 351, 353–4
Vaccine Safety Datalink (VSD) 130, 354–5, 391
validity of data 205–27
assessment of self-reported data 221
association 211–12
automated databases 139–41, 159–60, 221–4
best practices 218–20, 224–5
case examples 213–14, 216–17, 223–4
comparator selection 221
data resources comparison 191–2, 194
field studies 179–80
future developments 225–6
measurement error 206–12, 220, 226
medical condition type 216–17
medication class 214
misclassification of variables 209–12, 226
patient population 215–16, 218
prescribing practices 346–7
quantitative measurement of reliability 206, 208
quantitative measurement of validity 206–8, 219
questionnaire design 214–15, 218–20
recall accuracy 212–18, 220
self-reported diagnosis and hospitalization
data 216–18
self-reported drug data 212–16
timing of diagnosis and emotional effects on patient 217–18, 220
variability of data 304–5, 311–12, 361
Veterans Affairs (VA) health care 135–6, 138–44, 223–4, 344
VigiBase 108, 114
volume data 342
volume of distribution 42–3, 45–6, 48
voluntariness 259–60

warning and failure to warn 87–9, 93
Weber effect 113–14
weighted least squares linear regression 305
World Health Organization (WHO)
drug approval 12–13
drug utilization studies 339, 342, 344, 346
pharmacovigilance and spontaneous reporting 101, 106, 108–9, 111, 114–15
vaccine safety 351
WHO Drug Dictionary 187
Wyeth v. Levine 90